In animal models of asthma, selective EGFR inhibitors such as AG1478 and gefitinib, significantly reduced airway smooth muscle hyperplasia/remodeling, eosinophil recruitment, inflammation, AHR and epithelial and goblet cell proliferation [27, 33, 34]. The gene discussed is AHR; the disease is asthma.